From your perspective, what are the key strengths of this trial, and what are some of the potential weaknesses or limitations that practitioners should keep in mind when interpreting these results?

Yeah, I absolutely agree.

The QUINT III trial really does stand out as a rigorous and thoughtful study.

The strengths of the study that I would like to highlight are the study's large sample sizes, multinational and multicenter design.

There were 127 research sites that were included throughout multiple countries, which helps to increase our generalizability of the study.

The QUINT3 trials duration following the patients for an extended duration of 78 weeks to provide meaningful evaluation of F-acetora's long-term safety, tolerability, and efficacy.

And then to add on to that, to meet 99% statistical power, the study needed approximately 798 participants, but ended up recruiting 986 participants and maintaining a high retention rate throughout the study.

If Satora receives FDA approval, how do you see this changing the way pharmacists and other clinicians approach basal insulin therapy in patients with type 2 diabetes? And who might be the ideal candidates for this agent? And who might it not be appropriate for?